Literature DB >> 10898693

Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.

M K Jordan1, M A Polis, G Kelly, P K Narang, H Masur, S C Piscitelli.   

Abstract

Ten human immunodeficiency virus-infected patients were given rifabutin in addition to fluconazole and clarithromycin. There was a 76% increase in the area under the concentration-time curve of rifabutin when either fluconazole or clarithromycin was given alone and a 152% increase when both drugs were given together with rifabutin. Patients should be monitored for adverse effects of rifabutin administered concomitantly with clarithromycin and/or fluconazole.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898693      PMCID： PMC90031          DOI： 10.1128/AAC.44.8.2170-2172.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-08-20

2.  The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.

Authors:  A Cato; J Cavanaugh; H Shi; A Hsu; J Leonard; R Granneman
Journal:  Clin Pharmacol Ther       Date:  1998-04       Impact factor: 6.875

3.  Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

Authors:  R Hafner; J Bethel; M Power; B Landry; M Banach; L Mole; H C Standiford; S Follansbee; P Kumar; R Raasch; D Cohn; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  A model based assessment of redistribution dependent elimination and bioavailability of rifabutin.

Authors:  R C Li; P K Narang; I Poggesi; M Strolin-Benedetti
Journal:  Biopharm Drug Dispos       Date:  1996-04       Impact factor: 1.627

Review 5.  The clinical pharmacokinetics of rifabutin.

Authors:  T F Blaschke; M H Skinner
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

6.  A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.

Authors:  S D Shafran; J Singer; D P Zarowny; P Phillips; I Salit; S L Walmsley; I W Fong; M J Gill; A R Rachlis; R G Lalonde; M M Fanning; C M Tsoukas
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

7.  A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.

Authors:  S C Piscitelli; G Kelly; R E Walker; J Kovacs; J Falloon; R T Davey; S Raje; H Masur; M A Polis
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

8.  Determination of rifabutin in human plasma by high-performance liquid chromatography with ultraviolet detection.

Authors:  Y Y Lau; G D Hanson; B J Carel
Journal:  J Chromatogr B Biomed Appl       Date:  1996-02-09

9.  Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients.

Authors:  C B Trapnell; P K Narang; R Li; J P Lavelle
Journal:  Ann Intern Med       Date:  1996-03-15       Impact factor: 25.391
  9 in total
  5 in total

1.  Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Authors:  Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

2.  A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections.

Authors:  Miranda Monk; Ramy Elshaboury; Alexander Tatara; Sandra Nelson; Monique R Bidell
Journal:  Microbiol Spectr       Date:  2022-05-11

3.  Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Authors:  Stefanie Hennig; Elin M Svensson; Ronald Niebecker; P Bernard Fourie; Marc H Weiner; Stefano Bonora; Charles A Peloquin; Keith Gallicano; Charles Flexner; Alex Pym; Peter Vis; Piero L Olliaro; Helen McIlleron; Mats O Karlsson
Journal:  J Antimicrob Chemother       Date:  2016-01-31       Impact factor: 5.790

Review 4.  Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.

Authors:  Jiezhong Chen; Kenneth Raymond
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-02-15       Impact factor: 3.944

5.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.